Multiple Sclerosis Clinical Trial
— PALMS-IIOfficial title:
A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology
Verified date | July 2018 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Development and pilot testing of a cognitive self-management intervention for persons with multiple sclerosis (PwMS) emphasizing physical activity (PA) delivered via web-based video conference.
Status | Completed |
Enrollment | 16 |
Est. completion date | June 1, 2018 |
Est. primary completion date | June 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of clinically definite MS documented by their healthcare provider - Age 21 to 70 - Capable of understanding and complying with the study protocol - Able to read and write in English - Stable disease at the time of entry into the study (relapse free for at least 90 days) - Willing to participate in an 8-week study promoting physical activity, MS self-management and compensatory cognitive strategies, and data collection - Have subjective concerns about their cognitive functioning (score = 10 on the 20-item Perceived Deficits Questionnaire) - Any gender - Any ethnic/racial group Exclusion Criteria: - Currently pregnant or plan to be - Diagnosed with cardiovascular or respiratory disease, other medical causes of dementia or other neurological disorders that may impact cognition or emotions - Evidence of major psychiatric disorder - Major functional limitations that preclude them from participating in the study |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas at Austin | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline NIH Toolbox Picture Vocabulary Test at 8-weeks (post-intervention) | Test of vocabulary knowledge | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Oral Reading Recognition at 8-weeks (post-intervention) | Test of oral reading (decoding) skills | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Flanker Inhibitory Control and Attention Test at 8-weeks (post-intervention) | Test of executive function - the capacity to plan, organize and monitor the execution of behaviors that are strategically directed in a goal-oriented manner) and attention (allocation of one's limited capacities to deal with an abundance of environmental stimulation) test. | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Dimensional Change Card Sort Test at 8-weeks (post-intervention) | Test of attention - the allocation of one's limited capacities to deal with an abundance of environmental stimulation) test. | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox List Sorting Working Memory Test at 8-weeks (post-intervention) | Test of working memory - the capacity of an individual to hold information in a short-term buffer and manipulate the information. | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Oral Symbol Digit Test at 8-weeks (post-intervention) | Test of processing speed - the amount of time it takes to mentally process a set amount of information, or the amount of information that can be processed within a certain unit of time. It is a measure that reflects mental efficiency. | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Pattern Comparison Processing Speed Test at 8-weeks (post-intervention) | Test of processing speed - the amount of time it takes to mentally process a set amount of information, or the amount of information that can be processed within a certain unit of time. It is a measure that reflects mental efficiency. | Baseline and 8-weeks (post intervention) | |
Primary | Change from Baseline NIH Toolbox Picture Sequence Memory Test at 8-weeks (post-intervention) | Test of episodic memory - the acquisition, storage and retrieval of new information. It involves conscious recollection of information learned within a context. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Multiple Sclerosis Self-Management Scale (MSSM) at 8-weeks (post-intervention) | A 24-item self-report instrument developed specifically to address self-management in persons with MS. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Medications and Treatments 4a at 8-weeks (post-intervention) | A 4-item self-report measure of confidence in managing medication schedules of different complexity. Items also assess managing medication and other treatments in challenging situations such as when traveling, when running out of medication, and when adverse effects are encountered. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Symptoms 4a at 8-weeks (post-intervention) | A 4-item self-report measure of confidence to manage/control symptoms, to manage symptoms in different settings (home, public place, an unfamiliar place) and to keep symptoms from interfering with work, sleep, relationships or recreational activities. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Daily Activities 4a at 8-weeks (post-intervention) | A 4-item self-report measure of confidence in performing various activities of daily living (ADLs) without assistance. Items also assess exercise, sexual activities and managing activities in challenging situations (traveling, bad weather). | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Neuro-Quality of Life (QoL) Short Form v2.0 - Cognitive Function at 8-weeks (post-intervention) | An 8-item self-report measure of mental acuity, concentration, verbal and nonverbal memory, verbal fluency, and perceived changes in these cognitive functions. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Neuro-QoL Short Form v1.0 - Depression at 8-weeks (post-intervention) | An 8-item self-report measure of negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), as well as decreased positive affect and engagement (loss of interest, meaning, and purpose). Somatic symptoms (changes in appetite, sleeping patterns) are not included, which eliminates consideration of these items' confounding effects when assessing patients with comorbid physical conditions. Assesses depression over the past seven days. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Neuro-QoL Short Form v1.0 - Fatigue at 8-weeks (post-intervention) | An 8-item self-report measure of fatigue symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. Assesses fatigue over the past seven days. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Neuro-QoL Short Form v1.0 - Sleep Disturbance 4a at 8-weeks (post-intervention) | An 8-item self-report measure of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. Sleep Disturbance does not focus on symptoms of specific sleep disorders, nor does it provide subjective estimates of sleep quantities (total amount of sleep, time to fall asleep, amount of wakefulness during sleep). Assesses sleep disturbance over the past seven days. | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Physical Activity - steps at 8-weeks (post-intervention) | Accelerometer step count | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Physical Activity - activity count at 8-weeks (post-intervention) | Accelerometer activity count | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Sleep quality - sleep latency at 8-weeks (post-intervention) | Accelerometer sleep latency | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Sleep quality - wake after sleep onset at 8-weeks (post-intervention) | Accelerometer wake after sleep onset | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Sleep quality - total sleep time at 8-weeks (post-intervention) | Accelerometer total sleep time | Baseline and 8-weeks (post intervention) | |
Secondary | Change from Baseline Sleep quality - sleep efficiency at 8-weeks (post-intervention) | Accelerometer sleep efficiency | Baseline and 8-weeks (post intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |